相关实验视频

Updated: Feb 28, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

人体肠道微生物群与阿尔茨海默氏病的病原性联系:一项探索性临床研究

Tadashi Ohara¹, Yasuyuki Taki^1,2

¹Department of Aging Research and Geriatric Medicine, Institute of Development, Aging and Cancer, Tohoku University, Miyagi 980-8575, Japan.

|February 27, 2026

概括

这项研究探讨了日本阿尔茨海默病 (AD) 患者的肠-大脑轴. 虽然没有发现显著的肠道微生物群差异,但微生物群可能有助于识别AD风险.

科学领域:

神经科学是一个神经科学.
微生物学微生物学
胃肠病学胃肠病学

背景情况:

肠-大脑轴越来越多地与神经系统疾病有关.
在日本人群中对微生物群和阿尔茨海默病 (AD) 的研究是有限的.
了解肠道微生物组在阿尔茨海默病变的产生中的作用至关重要.

研究的目的:

在日本队列中调查肠道微生物组成与阿尔茨海默病 (AD) 之间的关联.
探索大脑-肠轴在阿尔茨海默病发病过程中的潜在作用.
为了确定与AD风险相关的特定细菌物种.

主要方法:

使用16S rRNA基因测序进行便微生物组合分析.
10名阿尔茨海默病患者和21名健康成年人之间的微生物群的比较.
包括三个不同的年龄组的参与者.

主要成果:

一些细菌物种,如Ruminococcus inulinivorans和Ruminococcus torques在AD组中更为丰富.
在健康的成年人中,Agathobacter rectalis,Bacteroides uniformis和Clostridium butyricum的数量更为丰富.
单个细菌种群的差异没有达到统计学意义.

结论:

初步发现表明,阿兹海默症患者和健康人群之间的便微生物群没有显著差异.
肠道微生物群的组成可以作为阿尔茨海默病风险的潜在指标.
需要进一步的研究来确定用于AD查和预防策略的特定细菌物种.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在MCI中,MCI是MCI.大脑肠轴脑肠轴人的肠道微生物群病变的发生和发病.在临床前的阿尔茨海默氏病.

更多相关视频

Applying Advanced In Vitro Culturing Technology to Study the Human Gut Microbiota

Applying Advanced In Vitro Culturing Technology to Study the Human Gut Microbiota

Published on: February 15, 2019

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...